Skip to content

Natural History in Children up to 16 Years With Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Longitudinal Study of the Natural History of Two Autosomal Recessive Non Syndromic Deafness (DFNB1A and DFNB9) in Children up to 16 Years of Age

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05402813
Acronym
Otoconex
Enrollment
180
Registered
2022-06-02
Start date
2022-11-18
Completion date
2031-06-01
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AUNB1, Congenital Deafness, DFNB1A, DFNB9, GJB2 Gene Mutation, OTOF Gene Mutation, Sensorineural Hearing Loss, Bilateral

Brief summary

The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.

Detailed description

The study aims to: * better describe the prevalence of cases of DFNB1A and DFNB9, including the type of mutations, and to assess the clinical course of the disease in children up to 16 years of age who have a mild to profound deafness. * better understand the audiological and genetic characteristics of the participants with congenital versus evolutive DFNB1A and DFNB9 deafness.

Interventions

OTHERPure Tone Audiometry Assessment

Collection of Pure Tone Audiometry data performed in routine practice during study period

OTHERQuality of Life Questionnaires

Collection of Quality of Life questionnaire's answers during study period

Sponsors

Sensorion
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 16 Years
Healthy volunteers
No

Inclusion criteria

Main Inclusion Criteria: Participants meeting all the following main inclusion criteria will be eligible to participate in the study: * Aged ≤ 16 years on the date of signed informed consent for cohort 1 and ≤ 10 years for cohort 2; * With a diagnosis of non-syndromic, bilateral, mild to profound, sensorineural hearing loss (according to the American Speech Language-Hearing Association); * With documented genotyping results showing mutation(s) in GJB2 or OTOF genes; * Written informed consent as required by local regulations. * Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)

Exclusion criteria

Participants presenting with any of the following main

Design outcomes

Primary

MeasureTime frameDescription
Audiological characteristicsUp to 4 yearsPure Tone Audiometry, thresholds on 500, 1000, 2000, 4000 Hz Speech audiometry
Electrophysiological characteristics: ABRUp to 4 yearsAuditory Brainstem Response, thresholds
Electrophysiological characteristics: OAEUp to 4 yearsOtoacoustic Emissions thresholds

Secondary

MeasureTime frameDescription
Genotypic and phenotypic characterisation1 DayGenotypic and phenotypic characterisation of the population will be assessed in Cohort 1a. Frequency of autosomal recessive 1 and 9 deafness (GJB2 and OTOF genes) and type of mutations will be evaluated among the screened population of male and female children aged \< 16 years, with a diagnosis of bilateral mild to profound, sensorineural, non-syndromic hearing loss.
Hearing-related Quality of Life questionnaireUp to 4 yearsThe Hearing Environments And Reflection on Quality of Life (HEAR-QL) measurement questionnaires will be used to assess the quality of life of children. Depending on child's age, the HEAR-QL questionnaires will be completed either by parents/caregivers (child aged 2 to 6 years) either by the child (child aged 7 to 12 years). The items of the questionnaires are focused on situations affecting interactions with family and friends, participation in social and school activities, and impact of Hearing Loss on the child's emotional well being. Children/parents will be asked to rate how frequently each item was a problem for them/child in the past month using the following response choices: "never" (1), "almost never" (2), "sometimes" (3), "often" (4), or "Almost always" (5). Scores are transformed with 1=100, 2=75, 3=50, 4=25, and 5=0 points. Higher scores indicate higher perceived Quality Of Life.

Countries

France

Contacts

CONTACTLionel HOVSEPIAN, MD
lionel.hovsepian@sensorion-pharma.com+33 (0)7 86 31 13 76
PRINCIPAL_INVESTIGATORNatalie LOUNDON, MD

Necker Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026